Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Radue, EW; Stuart, WH; Calabresi, PA; Confavreux, C; Galetta, SL; Rudick, RA; Lublin, FD; Weinstock-Guttman, B; Wynn, DR; Fisher, E; Papadopoulou, A; Lynn, F; Panzara, MA; Sandrock, AW; SENTINEL Investigators.
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
J Neurol Sci. 2010; 292(1-2):28-35
Doi: 10.1016/j.jns.2010.02.012
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Members Med Uni Graz:
- Seifert-Held Thomas
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p<0.001). Compared with IFNbeta-1a alone, add-on natalizumab therapy resulted in a smaller increase in mean T1-hypointense lesion volume after 2 years (1821.3mm(3) versus 2210.5mm(3); p<0.001), a smaller mean number of new T1-hypointense lesions over 2 years (2.3 versus 4.1; p<0.001), and a slower rate of brain atrophy during the second year of therapy (-0.31% versus -0.40%; p=0.020). Natalizumab add-on therapy reduced gadolinium-enhancing, T1-hypointense, and T2 MRI lesion activity and slowed brain atrophy progression in patients with relapsing MS who experienced disease activity despite treatment with IFNbeta-1a alone.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Antibodies, Monoclonal - therapeutic use
- Brain - pathology
- Drug Therapy, Combination -
- Female -
- Humans -
- Immunologic Factors - therapeutic use
- Interferon-beta - therapeutic use
- Magnetic Resonance Imaging -
- Male -
- Middle Aged -
- Multiple Sclerosis, Relapsing-Remitting - pathology Multiple Sclerosis, Relapsing-Remitting - therapy
- Patient Selection -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Natalizumab
- Interferon beta-1a
- Multiple sclerosis
- Integrin
- Adhesion molecule inhibitor
- Treatment
- Magnetic resonance imaging